GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background & Aims: Liraglutide, a Glucagon‐like peptide‐1(GLP‐1) analogue with 97% sequence identity to human GLP‐1, increases insulin secretion and insulin sensitivity. Its effect on non‐alcoholic fatty liver disease (NAFLD) remains poorly understood. In this study, we examined whether liraglutide can protect against inflammatory stress by inhibiting activation of c‐Jun N‐terminal protein kinase (JNK). Methods: ApoE KO and adiponectin (Acrp30) knockdown mice fed a high‐fat diet (HFD) were treated with liraglutide (1 mg/kg, twice daily) for 8 weeks. Liver tissue was procured for histological examination, real‐time RT‐PCR and Western blot analysis. Results: The results showed that the combination of HFD, Acrp30 knockdown and ApoE deficiency had additive effects on the development of insulin resistance (IR) and NAFLD. Administration of liraglutide prevented the development of HFD and hypoadiponectinaemia–induced IR and NAFLD in this model. Liraglutide also attenuated the expression of proinflammatory cytokines or transcription factor, including TNF‐α and NF‐κB 65, and the expression of two lipogenesis‐related genes, Acetyl‐CoA Carboxylase (ACC) and fatty acid synthase (FAS). These changes were accompanied by elevated plasma of Acrp30, increased Acrp30 mRNA, AMP Kinase phosphorylation, and decreased mitogen‐activated protein kinase 4 (MKK4) mRNA expression and JNK phosphorylation. Conclusions: Our study also showed potent inhibitory effects of liraglutide on MKK 4/JNK signalling which may be a mechanism for the observed improved insulin sensitivity and inflammatory stress induced by HFD and hypoadiponectinaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487
Measurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A., Papouchado, B. G., Li, Z., Lopez, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01774.x · Cited by 597 · cited 1×
“In addition to insulin resistance (IR), proinflammatory cytokines, such as TNF-a and interleukin-6 (IL-6) play a pivotal role in the pathogenesis of NAFLD (3, 4).”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
JNK1 but not JNK2 promotes the development of steatohepatitis in mice
Schattenberg, J. M., Singh, R., Wang, Y., Lefkowitch, J. H., Rigoli, R. M., Scherer, P. E., & Czaja, M. J. (2006) · Hepatology · doi:10.1002/hep.20999 · Cited by 384 · cited 1×
“Therefore, JNK signalling has been considered a major pathogenetic factor in the development of steatohepatitis (8).”
BackgroundSharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 1×
“In vitro studies showed that GLP-1 receptor agonists reduce fat accumulation in HepG2 and Huh7 cells (9).”
BackgroundLee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158
Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61
Research works printed but not linked: 13
- 10.1056/NEJMra011775 · DOI · Paper page
- 10.1002/hep.20973 · DOI · Paper page
- 10.1136/gut.48.2.206 · DOI · Paper page
- 10.1126/science.1071924 · DOI · Paper page
- 10.1002/hep.23929 · DOI
- 10.1016/j.jhep.2010.09.032 · DOI · Paper page
- 10.1210/en.2009-1166 · DOI · Paper page
- 10.1016/j.cyto.2008.10.006 · DOI
- 10.2337/diabetes.50.2.315 · DOI · Paper page
- 10.1007/BF03346561 · DOI
- 10.1055/s-2004-826172 · DOI · Paper page
- 10.1016/j.tem.2010.08.010 · DOI · Paper page
- 10.1016/S0959-437X(01)00258-1 · DOI · Paper page
Cited by
NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes
Godoy-Matos, A. F., Silva Júnior, W. S., & Valerio, C. M. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00570-y · Cited by 643
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Briefly, GLP-1 exists in the human body in two active forms, GLP-1 (7-36 amide) and GLP-1 (7-37), with the proportion of GLP-1 (7-36 amide) being higher (8, 9).”
BackgroundInfluentialGlucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
Ballestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 262
Bower, G., Toma, T., Harling, L., Jiao, L. R., Efthimiou, E., Darzi, A., Athanasiou, T., & Ashrafian, H. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1691-x · Cited by 256
Metadata
- Authors
- Zhang, L., Yang, M., Ren, H., Hu, H., Boden, G., Li, L., & Yang, G.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2013-02-24
- Volume
- 33
- Issue
- 5
- Pages
- 794-804
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2079094133
- Cited by
- 65
- References
- 10
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- National Natural Science Foundation of China (30871199, 81070640, 30971388 and 30771037)
- Doctoral Fund of Ministry of Education of China (20105503110002)
- Natural Science Foundation Key Project of CQ cstc (cstc2012 jjB10008)
- Special Foundation for Postdoctoral Project of CQ (Yu xm201103004)
- the American Diabetes Association grant (1-10-CT-06)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK. https://app.cochat.ai/papers/10.1111/liv.12120
- The paper
- Zhang, L., Yang, M., Ren, H., Hu, H., Boden, G., Li, L., & Yang, G. (2013). GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK. Liver International. https://doi.org/10.1111/liv.12120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.